Meeting
2015 ASCO Annual Meeting
Contribution of immune system and tumor-related interferon signaling to epirubicin response in triple-negative (TN) breast cancers.
Authors
Giampaolo Bianchini
San Raffaele Scientific Institute, Milan, Italy
Giampaolo Bianchini , Maurizio Callari , Takayuki Iwamoto , Michela Riba , Lucia Vigano' , Alberta Locatelli , Milvia Zambetti , Thomas Karn , Luca Gianni , Lajos Pusztai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Triple-Negative/Cytotoxics/Local Therapy
Track
Breast Cancer
Sub Track
Triple-Negative Breast Cancer
Citation
J Clin Oncol 33, 2015 (suppl; abstr 1081)
DOI
10.1200/jco.2015.33.15_suppl.1081
Abstract #
1081
Poster Bd #
195
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
A randomized phase III trial comparing two dose-dense, dose-intensified approaches (EPC and PM(Cb)) for neoadjuvant treatment of patients with high-risk early breast cancer (GeparOcto).
First Author: Andreas Schneeweiss
Poster
2014 ASCO Annual Meeting
Prognostic significance of interferon regulating factor 4 (IRF4) in node-negative breast cancer.
First Author: Marcus Schmidt
Poster
2019 ASCO Annual Meeting
Germline mutation status and therapy response in high-risk early breast cancer: Results of the GeparOcto study (NCT02125344).
First Author: Esther Pohl-Rescigno
Poster
2018 ASCO Annual Meeting
Neo-/adjuvant phase III trial to compare intense dose-dense (idd) treatment with EnPC to tailored dose-dense (dt) therapy with dtEC-dtD for patients with high-risk early breast cancer: Results on pathological complete response (pCR) for patients treated within the neoadjuvant setting.
First Author: Volker Moebus